Skip to main content

Table 1 Characteristics of the 8 patients with CHH treated by rhLH and rh FSH infusion

From: Growth and descent of the testes in infants with hypogonadotropic hypogonadism receiving subcutaneous gonadotropin infusion

Patients

Classification

Age at onset of treatment (months)

Before treatment

After treatment

   

Testes position

Penile length (mm)

Time to descent (months)

Testes volume (ml)

Testes position

Penile length (mm)

Duration of treatment (months)

P1

CPHD

6

Non palpable

18

1

0.61

High scrotal

30

6

P2

CPHD

11

Non palpable

20

4

2

Intra-scrotal

33

6

P3

CPHD

10

High-scrotal

30

1

2,1

Intra-scrotal

70

6

P4

IHH

4.5

Non palpable

21

4

0.76

Intra-scrotal

30

6.5

P5

IHH

2.5

Non palpable

20

6

0.7

High-scrotal Intra-scrotal

35

6.5

P6

IHH

9

Non palpable

19

4

1,16

Intra-scrotal

40

5

P7

IHH

5

High-scrotal

28

4

0,89

Intra-scrotal

52

5

P8

IHH

0.25

High-scrotal

13

5

1,95

Intra-scrotal

30

6

  1. IHH isolated hypogonadotropic hypogonadism, CPHD Combined Pituitary Hormonal Deficits (CPHD)